Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) branch BYS30 particles obtained the drug clinical trial approval notice.
Baiyunshan (600332.SH) announced that recently, its subsidiary, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. decided to...
Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) announced that its subsidiary Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceutical Group Co., Ltd. has received the approval notice for clinical trials of a drug named BYS30 Granule from the National Medical Products Administration.
In accordance with the Drug Administration Law of the People's Republic of China and relevant regulations, the clinical trial application for BYS30 Granule (CXZL2400072) submitted on October 29, 2024, has been reviewed and found to meet the requirements for drug registration. After further refinement of the clinical trial plan, the drug is approved for clinical trials for the treatment of knee osteoarthritis.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
